West Pharmaceutical CEO Highlights GLP-1 And Biologics Momentum
West Pharmaceutical reported Q2 earnings and revenue beat, higher 2026 guidance, and continued strength in GLP-1 and HVP products.
West Pharmaceutical did better than expected this quarter and feels confident about next year, especially because more people are using GLP-1 medicines (weight and diabetes drugs) that need special packaging. When a company that makes medicine containers sees strong demand, it hints that the medicines themselves are selling well.
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only — not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.